A Highly Potent Apomorphine Derivative Enhancing Neurite Outgrowth via Nrf2 Activation.

Tamaki Ishima, Hitoshi Osaka, Ryozo Nagai, Kenichi Aizawa

Abstract read

In one paragraph

Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tamaki IshimaDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke 329-0498, Japan.ORCID 0009-0002-2309-265X

Hitoshi OsakaDepartment of Pediatrics, Jichi Medical University, Shimotsuke 329-0498, Japan.ORCID 0000-0002-1320-1165

Ryozo NagaiJichi Medical University, Shimotsuke 329-0498, Japan.

Kenichi AizawaDivision of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke 329-0498, Japan.

Funding

Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED) im0210625h0001, 17ek0109270s0301, 21ek0109511h0001, 22ek0109511h0002, 23ek0109511h0003, and 24ek0109625s0602the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Sup-porting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED JP21am0101120

6 · The paper itself

Abstract

Apomorphine (APO), a dopamine agonist, activates nuclear factor erythroid 2-related factor 2 (Nrf2) and exerts antioxidant effects, making it a promising candidate for neuroprotection against oxidative stress. This study evaluated neuroplasticity-enhancing properties of newly synthesized APO derivatives, focusing on their ability to promote neurite outgrowth in PC12 cells under nerve growth factor (NGF) stimulation. D55, an APO derivative, retains the hydroxyl group at APO's 11th position while substituting the 10th with an ethoxy group. D55 exhibited the highest potency (EC

Indexed as

apomorphine derivativesedaravoneneurite outgrowthneurodegenerative diseasesNrf2 activationtherapeutic agents

Identifiers

PMID40427418

DOI10.3390/antiox14050537

PMCPMC12108180

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.